This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Atreca ha un patrimonio netto totale di $10.8M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $26.3M e $15.6M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$21.39m
Patrimonio netto	US$10.76m
Totale passività	US$15.58m
Totale attività	US$26.34m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Jul 23

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Dec 08

Atreca GAAP EPS of -$0.72 misses by $0.02

Aug 08

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Jun 18

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Apr 22

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Mar 05

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Jan 25

Atreca: Safety Data Brought Down Stock

Sep 10

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Sep 02

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

May 14

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Jan 29

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Dec 07

Atreca EPS misses by $0.06

Nov 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $24.7M ) di BCEL superano le sue passività a breve termine ( $15.6M ).

Passività a lungo termine: BCEL non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BCEL è esente da debiti.

Riduzione del debito: BCEL non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: BCEL ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: BCEL ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 12.4 % ogni anno

This company listing is no longer active

Atreca Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Atreca, Inc. Files Form 15

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

Atreca Receives Notice from the Nasdaq Stock Market

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane